Piramal Pharma Limited reported earnings results for the fourth quarter and full year ended March 31, 2024. For the fourth quarter, the company reported sales was INR 25,523.6 million compared to INR 21,635.8 million a year ago. Revenue was INR 25,787.4 million compared to INR 21,880.8 million a year ago. Net income was INR 1,012.7 million compared to INR 501.1 million a year ago. Basic earnings per share from continuing operations was INR 0.77. Diluted earnings per share from continuing operations was INR 0.77.
For the full year, sales was INR 81,711.6 million compared to INR 70,815.5 million a year ago. Revenue was INR 83,465.5 million compared to INR 73,066.6 million a year ago. Net income was INR 178.2 million compared to net loss of INR 1,864.6 million a year ago. Basic earnings per share from continuing operations was INR 0.14. Diluted earnings per share from continuing operations was INR 0.14.